OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

OrthoPediatrics (KIDS) reported $52.41 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 17.3%. EPS of -$0.39 for the same period compares to -$0.30 a year ago.The reported revenue represents a surprise of +1.72% over the Zacks Consensus Estimate of $51.53 million. With the consensus EPS estimate being -$0.26, the EPS surprise was -50.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales by category- Trauma and deformity: $37.87 million versus the three-analyst average estimate of $38.91 million. The reported number represents a year-over-year change of +13.7%. Product sales by category- Sports medicine/other: $0.88 million versus $1.28 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -25.4% change. Product sales by category- Scoliosis: $13.66 million versus the three-analyst average estimate of $11.34 million. The reported number represents a year-over-year change of +33.9%. View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -1.7% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OrthoPediatrics Corp. (KIDS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks